{"id":3501,"date":"2014-01-02T16:13:52","date_gmt":"2014-01-02T16:13:52","guid":{"rendered":"\/?p=3501"},"modified":"2014-01-02T16:14:43","modified_gmt":"2014-01-02T16:14:43","slug":"intellicell-biosciences-inc-otcmktssvfc-gets-a-free-pump-from-stock-mister","status":"publish","type":"post","link":"\/articles\/intellicell-biosciences-inc-otcmktssvfc-gets-a-free-pump-from-stock-mister\/","title":{"rendered":"IntelliCell BioSciences, Inc. (OTCMKTS:SVFC) Gets a Free Pump From Stock Mister"},"content":{"rendered":"

\"1SVFC.png\"Stock Mister sent us a couple of email alerts on IntelliCell BioSciences, Inc (OTCMKTS:SVFC<\/a>) on December 27 and December 30. The disclaimer says that the promotional outfit hasn’t been compensated, but even so, Stock Mister’s recommendation did have its effect on the performance. <\/p>\n

Last Friday’s session proved to be rather good for SVFC<\/a>‘s shareholders. The ticker managed to shift around 68 million shares while registering gains of around 35%, but on Monday, the success was even greater. More than 127 million shares changed hands while the price jumped up by a massive 78%. Unfortunately, such disproportionate moves, especially when they are sparked by touting through the email, rarely last long and on Tuesday, SVFC<\/a> retraced its steps dropping by 23.5% and finishing the day at $0.0026 per share.<\/p>\n

On the whole, a typical behavior from a ticker that is put under the promotional spotlight, but the people who are looking for something more than a quick trade are probably wondering if SVFC<\/a> has even the slimmest of chances of displaying any sort of prolonged run towards the higher end of the charts. <\/p>\n

If you ask the company CEO, Dr. Steven Victor, he’ll probably say that it does. He published a letter to the shareholders on December 10 in which he said that he is really pleased with the progress his company is experiencing. The update speaks about things like “competitive advantages<\/em>“, “improving the balance sheet<\/em>“, “overcoming obstacles<\/em>“, “opening new facilities<\/em>” etc. and if you base your investment decision on Dr. Victor’s words alone, you’ll probably assume that SVFC<\/a> will very soon be a leader in the regenerative medicine business.<\/p>\n

Unfortunately, the chart at the beginning of the article suggests otherwise. In fact, less than a year ago, SVFC<\/a> was hovering around $0.20 per share whereas right now, it’s struggling with the double-zero levels.<\/p>\n

The cause for the devastating performance can be found in the company’s latest 10-Q. Here’s a quick summary of the most important figures as of September 30:<\/p>\n